Biotech · Public company · Tampa, FL, US

TuHURA Biosciences, Inc.

Ticker HURA · SEC CIK 0001498382

Track this companyFree. Adds TuHURA Biosciences, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials52 recruiting or active

Pipeline programs5From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availableNo recent cash burn filed

Pipeline5

IFx-Hu2.0Phase 3 · Advanced Or Metastatic Merkel Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
PembrolizumabPhase 3 · Advanced Or Metastatic Merkel Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
IFx-Hu2.0Phase 1 · Cutaneous Melanoma, Stage IIIClinicalTrials.gov · fetched Nov 12, 2026
IFx-Hu2.0Phase 1 · Cutaneous Squamous Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
IFx-Hu2.0Phase 1 · Merkel Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026

IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)PHASE1 · RECRUITING · started Jan 27, 2026ClinicalTrials.gov NCT06940440 · fetched Nov 12, 2026
Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell CarcinomaPHASE2_PHASE3 · RECRUITING · started Dec 11, 2025ClinicalTrials.gov NCT06947928 · fetched Nov 12, 2026
IFx-Hu2.0 for the Treatment of Patients With Skin CancerPHASE1 · COMPLETED · started Jun 10, 2021ClinicalTrials.gov NCT04925713 · fetched Nov 12, 2026
Immunotherapy With IFx-Hu2.0 Vaccine for Advanced Non-melanoma Skin CancersPHASE1 · COMPLETED · started Mar 3, 2020ClinicalTrials.gov NCT04160065 · fetched Nov 12, 2026
pDNA Intralesional Cancer Vaccine for Cutaneous MelanomaEARLY_PHASE1 · COMPLETED · started Nov 5, 2018ClinicalTrials.gov NCT03655756 · fetched Nov 12, 2026